![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SKYEPHARMA AND ENDO AGREE TO TERMINATE JOINT DEVELOPMENT OF PROPOFOL IDD-D FOR NORTH AMERICA
SKYEPHARMA AND ENDO AGREE TO TERMINATE JOINT DEVELOPMENT OF PROPOFOL IDD-D FOR NORTH AMERICA
April 21, 2006
SkyePharma PLC announces today that it has agreed with its North American partner Endo Pharmaceuticals to terminate the joint development of Propofol IDD-D, an injectable anaesthetic and sedative that was licensed to Endo in December 2002. SkyePharma is evaluating its options worldwide for this product, which remains under strategic review.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-21-2006/0004344536&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct